Biography

Philippe Lambin is a Clinician scientist, Radiation Oncologist, “ERC advanced & three ERC PoC grant laureate” respectively from 2016, 2017, 2020 & 2022 and pioneer in translational research with a focus on tumour hypoxia; Radiomics, genetically modified bacteria for cancer treatment and Decision Support Systems. He has a PhD in Molecular Radiation Biology and is part-time Professor at the University of Maastricht (Precision Medicine) and at the University of Eindhoven (“Functional Imaging”, until 2011). He is co-author of more than 642 peer reviewed scientific papers (more than 76K citations, Hirsch Index: 129 Google scholar, co-inventor of more than 22 patent families (filed or submitted) of which 10 are in the (pre)commercialization phase and (co) promoter of more than 79 completed PhD’s (2 with cum laude).

Moreover, Prof. P. Lambin has extensive experience with clinical trials. He has been one of the international experts in the Flims workshop “Methods in Clinical Cancer Research organised jointly by the FECS, AACR and ASCO and he is leading several clinical trials (see www.clinicaltrials.gov: his name is mentioned as Principal Investigator in more than 30 clinical trials). He has been also a member of the scientific committee of KWF (the main Dutch funding body in cancer research) and of the advice committee on protontherapy of CVZ (the Dutch medical insurance).

He has been and is currently involved in several successful European grants (e.g. CDPT, Biocare, Euroxy, Metoxia, Eureca, Artforce, RADIATE, Quick-Concept, Requite, BD2decide, SCANnTREAT, EuCanImage, CHAIMELEON, DRAGON, iCOVID, AUTO.DISTINCT, LIVINGVAC, OPTIMA, RADIOVAL ,ReverseTheAdvantage, AIDAVA, REALM, EUCAIM, GLIOMATCH…) including ImmunoSABR (6 millions €, a multicentric randomized trial in metastatic lung cancer comparing radiotherapy plus or minus immunotherapy) and the Marie Curie Training network PREDICT of which he is the initiator and the coordinator and two NIH grant (“Radiomics”) from the US.

His main areas of interest are directed towards translational research in tumour Biology with a specific focus on tumour hypoxia, functional imaging (Radiomics), lung and head and neck cancer. More recently, his interests have been directed towards hypoxia targeting, Hypoxia Activated Prodrugs, during immunotherapy, genetically modified bacteria as living medicine and the development of “AI-based treatment decision support system” based on multiparametric databases containing clinical, imaging, biological and therapeutic information, and taking into account patient preferences. The website he launched, predictcancer.org or ai4cancer.ai with validated predictive models has had more than 20.000 visitors from more than 133 countries.

He is one of the co-inventors of “Radiomics”, “Clinical Decision Support Systems”, “Distributed learning” from federated databases, genetically modified bacteria for cancer treatment, the combination of immunocytokines with radiation, Lymphocytes-Sparing Radiotherapy (LSRT, also named “Drugless Radiotherapy”) and MEDomics.

Few years ago, his research group received the highest possible score (‘excellent’ – 5 - on all aspects) by an international external review committee and was described as having a “world-leading position”. The reviewers added, “In large part, this is due to the inspirational leadership of Prof. P. Lambin who has done an outstanding job of building a world-class research program within a relatively short period of time”.
He is/was also a serial entrepreneur, founder and/or (non-)executive of: Oncoradiomics, Convert Pharmaceuticals, Comunicare (ex MedC2), LivingMed Biotech, Bactam. Most recently Convert Pharmaceuticals recently received the prestigious EIC Accelerator grant for "Tumagnostic" (ca. 5% acceptance rate) for the clinical phase I-IIa of an Hypoxia Activated Prodrug of second generation.